Advisory committee to assess DX-88 for HAE

FDA's Pulmonary-Allergy Drugs Advisory Committee will meet Feb. 4 to discuss the BLA for Dyax's hereditary angioedema treatment DX-88 (ecallantide). A positive recommendation from the panel would help DX-88 move forward as potentially the first product approved for the treatment of acute attacks of HAE. Under priority review at FDA, the BLA has an action date in late March (1"The Pink Sheet" DAILY, Sept. 24, 2008)